The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.
July 19th 2024
Rezatapopt has displayed early signals of efficacy and tolerability in p53 Y220C-mutated solid tumors.
Community Practice Connections™: 14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies
View More
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer
View More
B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence
View More
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
8th Annual School of Nursing Oncology™
August 10, 2024
Register Now!
Cancer Summaries and Commentaries™: Clinical Updates in RCC from Chicago
View More
San Diego Lung Symposia
September 7, 2024 - September 8, 2024
Register Now!
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?
View More
How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…
View More
The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape
View More
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
BURST CME™: Illuminating the Crossroads of Precision Medicine and Targeted Treatment Options in Metastatic CRC
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Neoadjuvant Chemoimmunotherapy Combination Is Active and Tolerable in Ovarian Cancer
April 13th 2023Jung-Yun Lee, MD, PhD, discusses the TRU-D trial within the context of prior negative trials to emphasize the need for more effective therapies in advanced-stage ovarian cancer, highlights key findings from TRU-D, and elaborates on future steps for this research.
Dr Fashemi on the Effect of Entinostat on Olaparib Responsiveness in Mouse HRP Ovarian Cancer Models
April 12th 2023Bisiayo Fashemi, PhD, discusses how the addition of entinostat to olaparib could help combat PARP inhibitor-resistance in homologous recombination proficient ovarian cancer, as well as the clinical significance of utilizing mouse organoid models to investigate such strategies.
First-line Senaparib Maintenance Meets PFS End Point in Advanced Ovarian Cancer
Maintenance therapy with senaparib improved progression-free survival vs placebo for patients with stage III/IV ovarian carcinoma, fallopian tube cancer, or primary peritoneal cancer who achieved a complete or partial response to first-line platinum-based chemotherapy, meeting the primary end point of the phase 3 FLAMES trial.
MVP-S Plus Low-Dose Cyclophosphamide Elicits Robust Responses in Recurrent Ovarian Cancer
April 10th 2023Oliver Dorigo, MD, PhD, explains how MVP-S leverages the DPX platform to produce persistent anti-survivin immune infiltration, highlights the antitumor activity and safety observed with the combination when given to patients with recurrent ovarian cancer, and describes additional research efforts underway.
Dr Zeybek on the Investigation of Neoadjuvant Olaparib in Newly Diagnosed BRCA-Mutant Ovarian Cancer
April 5th 2023Burak Zeybek, MD, discusses key results and clinical implications from the phase 1 NOW trial investigating neoadjuvant olaparib in patients with newly diagnosed, BRCA-mutant ovarian cancer.
Induction therapy with durvalumab plus chemotherapy and bevacizumab, followed by maintenance with olaparib plus durvalumab and bevacizumab, elicited a statistically significant and clinically meaningful improvement in progression-free survival compared with chemotherapy plus bevacizumab in patients with newly diagnosed advanced high-grade epithelial ovarian cancer who did not harbor BRCA mutations.
Dr Hogen on Survival Outcomes With Neoadjuvant Chemotherapy and ICS in Epithelial Ovarian Cancer
March 31st 2023Liat Hogen, MD, FRCSC, discusses the survival outcomes achieved with interval cytoreductive surgery following neoadjuvant chemotherapy in a study of patients with initial unresectable stage IV ovarian cancer.
Neoadjuvant Olaparib Proves Feasible, Aids Optimal Resection in BRCA-Mutant Ovarian Cancer
March 28th 2023Neoadjuvant treatment with olaparib prior to surgical resection and adjuvant chemotherapy was well tolerated and led to a 100% optimal resection rate in patients with newly diagnosed, BRCA-mutant ovarian, primary peritoneal, or fallopian tube cancer.
Niraparib Maintenance Does Not Produce Long-term OS Benefit in Recurrent Ovarian Cancer
March 27th 2023Maintenance niraparib did not produce a statistically significant overall survival benefit compared with placebo in patients with recurrent ovarian cancer, according to data from an updated exploratory OS analysis of the phase 3 ENGOT-OV16/NOVA study.
Dr Coleman on Response Rates With Mirvetuximab Soravtansine in Ovarian Cancer
March 27th 2023Robert L. Coleman, MD, FACOG, FACS, discusses an analysis of the phase 3 SORAYA trial evaluating response rates in patients with platinum-resistant ovarian cancer who received mirvetuximab soravtansine at different points in their disease course.
Olaparib Plus Selumetinib Produces Clinical Benefit in RAS-Mutated Ovarian and Endometrial Cancer
March 27th 2023The recommended phase 2 dose of olaparib plus selumetinib generated a clinical benefit in patients with endometrial or ovarian cancer harboring RAS mutations, according to findings from the dose-expansion portion of the phase 1b SOLAR trial.
Dr. Brown on the Use of PARP Inhibitors in the Upfront and Recurrent Settings in Ovarian Cancer
March 17th 2023Jubilee Brown, MD, professor, director, gynecologic oncology, Levine Cancer Institute, Atrium Health, discusses benefits associated with PARP inhibitor maintenance therapy in the upfront and recurrent settings of ovarian cancer.
PARP Inhibitors Redefine the Rapidly Changing Ovarian Cancer Landscape
March 15th 2023Erin K. Crane, MD, MPH, describes practice-changing findings from upfront trials with niraparib and olaparib, contextualizes the significance of the manufacturer restrictions of later-line PARP inhibitors for ovarian cancer, and predicts further research efforts in this population.
Enrollment Begins for Phase 2 Trial of IMNN-001 Plus Bevacizumab/Chemo in Advanced Ovarian Cancer
Enrollment has commenced for a phase 2 trial investigating the DNA-based interleukin-12 immunotherapy IMNN-001 in combination with bevacizumab and chemotherapy in patients with advanced ovarian cancer.